Inoculation programme will be expanded to cover 12- and 13-year-old boys in EnglandBoys aged 12 and 13 in England are to be vaccinated against the cancer-causing human papilloma virus (HPV), the government has said.The decision, announced on Tuesday, comes after theJoint Committee on Vaccination and Immunisation (JCVI) recommended last week that the HPV vaccination, which protects girls against cervical cancer, should be extended to boys. It followed growing calls for theinoculation programme to be expanded.Continue reading…
A physician’s recommendation should advise AA mothers on the risk of HPV and the importance of HPV vaccination at an early age to reduce cervical cancer risk. It should further address mothers’ perceived disadvantages of HPV vaccination (eg, side effects). Incorporating this information in physician recommendation practices could increase HPV vaccination rates with implications in reducing the cervical cancer burden among this high-risk population.
CONCLUSION: Currently, the anti-HPV national vaccination program combined with cervical cancer screening according to 5-year periodicity present the best cost-effective strategy for cervical cancer prevention in Tunisia. This study gives Tunisian decision makers a basis for structured planning and cost apportionment to ensure effective roll-out of the cervical cancer prevention strategies.
PMID: 29983258 [PubMed – as supplied by publisher]
Conclusions In this benchmark study, current, long term users of HC and current smokers of ≥5 cigarettes/day were each at increased risk of developing CIN 2/3. Findings support smoking cessation in relation to decreasing the risk of pre-cancerous lesions and reinforce the continuing need for cervical screening for cancer prevention in vaccinated and unvaccinated populations.
The human papilloma virus (HPV) vaccination programme in adolescent girls has led to a dramatic fall in the number of young women carrying the infection which can cause cervical cancer in England, a study published online in the Journal of Infectious Diseases has shown
(Barcelona Institute for Global Health (ISGlobal)) A study in Mozambique reveals that a majority of adolescent girls interviewed would be willing to get vaccinated against Human Papilloma Virus (HPV) if the vaccine was available in the country. These results are encouraging with regard to vaccine introduction and reducing mortality associated with cervical cancer in Mozambique. The investigation was led by the Manhi ç a Health Research Center (CISM) and ISGlobal, an institution supported by ” la Caixa ” Foundation
THURSDAY, May 17, 2018 — Human papillomavirus (HPV) vaccines protect against cervical precancer in adolescent girls and young women, according to a review published online May 9 in the Cochrane Library.
Marc Arbyn, M.D., from the Belgian Cancer…
AbstractHuman Papilloma Virus (HPV) is the most common sexually transmitted disease with over 14 million infections in 2008. Certain HPV types have been identified in up to 70% of cases of cervical and anal cancers. Despite being safe and effective, HPV vaccination rates remain low. Vaccination and demographic data was collected pre-and post-intervention. Among 13 thru 17-year-old cohort females were significantly more likely to be fully vaccinated. Assessment also found that patients insured by Medicaid were significantly more likely to be fully vaccinated than patients insured privately. Post-intervention vaccination rat…
Conclusions: Attitudes regarding their child being vaccinated against HPV were positive among Polish parents, even though awareness and knowledge of HPV in this group were low. Most of the significant factors that influenced their willingness were modifiable, such as being informed about HPV and having positive attitudes toward vaccines. Future interventions should focus specifically on vulnerable subgroups, such as unemployed parents.
When the HPV vaccine first hit the U.S. market in 2006, it was approved only for girls. Boys got the green light three years later — but a new study suggests there’s still a gender gap in vaccination rates.
The HPV vaccine — administered in either two or three doses — protects against human papillomavirus, a common sexually transmitted disease that can lead to cervical, vaginal, anal, penile, mouth and throat cancers. The Centers for Disease Control and Prevention (CDC) recommends that all children get the vaccine when they’re 11 or 12 years old, though it’s approved for use in people up…
CONCLUSION: Neither message had effect on intent to vaccinate, highlighting need for research to identify successful messaging strategies for HPV. Exploratory analyses suggest among parents with ‘Low’ vaccine confidence at baseline, the cervical cancer framed message may be more effective in changing intention than the CDC message or non-vaccine control. Future work should target groups with ‘Low’ or ‘Medium’ vaccine confidence at baseline – they may be more amenable to change, and more receptive to disease-salient messaging.
CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, Reference #: NCT03002324.